Related Experiment Video
Updated: Mar 15, 2026
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
10.1K
GLP-1 as a target for therapeutic intervention
Surya Panicker Rajeev1, John Wilding1
1Obesity and Endocrinology Clinical Research, Institute of Ageing and Chronic Disease, University of Liverpool, United Kingdom.
Current Opinion in Pharmacology
|September 5, 2016
Summary
Glucagon-like peptide receptor agonists effectively manage type 2 diabetes by improving glycemic control and reducing weight. Newer agents offer enhanced potency and duration, with combination therapies expanding treatment options.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Glucagon-like peptide receptor agonists (GLP-1 RA) are valuable in type 2 diabetes management due to their dual actions on glucose and weight.
- Current GLP-1 RA therapies offer significant HbA1c reduction and modest weight loss, with specific agents like liraglutide showing greater efficacy for obesity management.
Purpose of the Study:
- To review the current landscape and future directions of GLP-1 RA in managing type 2 diabetes and obesity.
- To highlight the therapeutic benefits, including glycemic control and adiposity reduction, offered by GLP-1 RA.
Main Methods:
- Review of existing literature on GLP-1 RA efficacy and applications.
- Analysis of current therapeutic options and emerging drug development trends.
Main Results:
- GLP-1 RA achieve HbA1c reductions of 1-2% and body weight loss of approximately 2-3 kg in type 2 diabetes mellitus (T2DM) patients.
- Liraglutide demonstrates significant weight loss at higher doses and is approved for obesity management.
- Combination therapies, including dual combinations with basal insulin, are increasingly available.
Conclusions:
- GLP-1 RA are a cornerstone in type 2 diabetes treatment, offering significant glycemic and weight benefits.
- The pipeline for GLP-1 RA includes more potent, longer-acting, and multi-action agents for the next decade.
- Advancements in GLP-1 RA therapy promise expanded and improved treatment strategies for metabolic disorders.
More Related Videos
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
01:23Dipeptidyl Peptidase 4 Inhibitors
876
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
876
01:15G Protein-coupled Receptors
18.9K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
18.9K
01:06Oral Hypoglycemic Agents: Glinides
821
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
821
01:15Hypoglycemia and Glucagon
1.2K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.2K
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.7K